There’s a new PSA test in health care. Hopefully it will prove more reliable than that other one.
In conjunction with the unveiling of the long-awaited ACO regulation by HHS, the FTC and Department of Justice issued a Joint Policy Statement setting forth their standards for conducting an expedited (90-day) antitrust review of applicants for ACO certification. The agencies explained that they will evaluate applicants’ market power based on the ACO’s share of services in each participant’s Primary Service Area (PSA) defined as the “lowest number of contiguous postal zip codes” from which the hospital or physician draws at least 75 percent of its patients for its services. The Statement summarized the antitrust implications of ACOs formed by hospitals or physician groups with large market shares in their markets:
ACOs with high PSA shares may pose a higher risk of being anticompetitive and also may reduce quality, innovation, and choice for both Medicare and commercial patients. High PSA shares may reduce the ability of competing ACOs to form, and could allow an ACO to raise prices charged to commercial health plans above competitive levels.
The antitrust enforcers were properly concerned with the risk that ACOs could become a vehicle for increasing or entrenching provider market power. Studies by academics, health policy experts and state governments have documented the impact of provider concentration on insurance premiums. Moreover, a post-reform merger wave may have increased the number of hospital and specialty physician markets and many areas are already served by dominant local providers. Inasmuch as the success of the ACO concept depends on its ability to spur delivery system change, the predictable intransigence of monopolistic providers presents an important issue. In this regard, it is heartening that the extended (and apparently controversial) regulation drafting process produced a result that promises to constrain the growth and exercise of market power.
Notably, the Policy Statement also removed some uncertainty that may have existed as to the application of prior antitrust enforcement actions and advisory opinions in the ACO context. For example, the Statement should provide some comfort to those organizing physician networks: ACOs that clear the CMS review of their integration efforts will almost certainly be regarded by FTC and DOJ as “clinically integrated” and hence not subject to strict not subject to the strict “per se” legal standard (More in a subsequent post on the issues raised in evaluating the competitive problems of ACOs in given circumstances).
Market power, however, remains a major sticking point in evaluating ACOs. Antitrust aficionados may question whether the PSA approach employed in the Policy Statement accurately indentifies markets or measures the market power of providers. As the FTC and DOJ themselves have found, zip code data gives a highly imperfect measure of health care markets. Moreover, there are significant problems in obtaining the necessary data regarding the total volume of services in the providers’ markets, particularly with regard to their services provided to commercial insurers and employers. However, it appears that the agencies will use this measure as a rough and ready starting point to identify potentially problematic ACOs and those that most obviously raise no competitive problems.
An important and, again, heartening, aspect of the Policy Statement is the agencies’ insistence that applicants with large market shares come forward with justifications and produce data and documents that would assuage competitive concerns. This should help expedite the process. (Though, if past practice with mergers is a guide, the 90-day clock will not start running until the ACO completes its production of all required information). The agencies make it clear that they will solicit the views of payers and employers before making their determination. Finally the CMS ACO regulation makes it clear that high PSA ACOs will not be approved unless the FTC or DOJ provides a clearance letter.
Not unlike the inexact science of medical diagnosis, the antitrust agencies are making do with the tools they have.
This post first appeared on Health Reform Watch, the web log of the Seton Hall University School of Law, Health Law & Policy Program.
Thomas “Tim” Greaney, JD, is Chester A. Myers Professor of Law and co-director of the Center for Health Law Studies at Saint Louis University School of Law. He is a member of the American Antitrust Institute Advisory Board and Academic Links Committee of the American Association of Health Lawyers.
In times of economic and political uncertainty, precious metals are known for outperforming stocks, bonds and real estate. Throw inflationary pressures into the mix and you have the conditions for an explosive rally in precious metals. As the Dow struggles to return to levels achieved ten years ago, the price of Gold has risen more than 400% and silver more than 550% in the same time frame!
In reality, the value of these metals has changed very little. Rather, their historical role as a store of value has begun to reassert itself, just as in every previous inflationary scenario in history. Our current economic situation and the underlying principles of our financial system all but assure that our dollars will continue to be devalued and the price of goods and services will continue to inflate in the years ahead. The record expansion of the money supply to “stimulate” the economy has accelerated this process. Unprecedented government budget deficits and huge trade imbalances leave few alternatives but to further debase the currency in order to service the interest on our national debt. And while all of these forces spell out difficult times ahead, the price of gold and silver relative to the dollar will only continue to rise—making them the ideal safeguard of wealth in any season.
Will the new PSA test be a success I guess only time will tell
Tim Greaney: “The antitrust enforcers were properly concerned with the risk that ACOs could become a vehicle for increasing or entrenching provider market power.”
Not all ACOs; the FTC’s concern is limited to fee-for-service groups, not those which rely on prepaid enrollees. “Federal regulators interpret prepaid group practice, including capitated IPAs, as pro-competitive rather than anti-competitive, however, since these entities accept financial risk for the cost of care and hence have the incentive to reduce costs to attract more patients.” (Robinson and Dolan. Accountable Care Organizations in California: Lessons for the National Debate on Delivery System Reform, 2010, p. 23.)
It should be noted that “ACOs in California care for 15.7 million prepaid enrollees. …Approximately 56% of individuals with commercial insurance, 45% of Medicare beneficiaries, and 52% of Medicaid beneficiaries receive their care from an ACO…; collectively these account for 54% of all persons with health insurance in the state.” (Ibid, p. 6) “A key differentiator of the California experience is the prevalence of capitation as a payment method, whereas other geographies use mostly fee-for-service even for large multispecialty medical groups. (p.12)
Just one more bureaucratic maze layered on top of existing ones. In the end, an army of wonks will be fully employed in arguing whether it saved any money or not, in which endeavors they will be unable to measure the implementation costs.
– Medicare fee-for-service beneficiaries will be retroactively assigned to ACOs based on primary care utilization during a performance year. “We are proposing to assign beneficiaries for purposes of the Shared Savings Program to an ACO if they receive a plurality of their primary care services from primary care physicians within that ACO.”
– Beneficiaries will not be assigned to more than one ACO.
– Beneficiaries will not receive advance notice of their ACO assignment. However, providers participating in ACOs will be required to post signs in their facilities indicating their participation in the program and to make available standardized written information to Medicare fee-for-service beneficiaries whom they serve. Additionally, all Medicare patients treated by participating providers must receive a standardized written notice of the provider’s participation in the program and a data use opt-out form.
“The Engelberg Center provides about 100 health systems with access to its “Learning Network,” a collaborative between Brookings and the Dartmouth Institute for Health Policy & Clinical Practice. The center has charged $2,500 or more to members to join, depending on the type of health system. The network produces conferences, newsletters, webinars and access to ACO experts, such as Engelberg Center Director Mark McClellan and Dartmouth Center for Population Health Director Elliott Fisher. Fisher and McClellan, who was Food and Drug Administration commissioner under President George W. Bush and also administrator for the Centers for Medicare and Medicaid Services, are longtime proponents of the ACO concept.”
Continues to be the driver.